FierceBiotechCAR-T 2.0? A split, universal and programmable systemFierceBiotechRecent FDA approvals have validated the use of chimeric antigen receptor T cells (CAR-Ts) to fight blood cancers, but the technology is still far from perfect. Researchers w… Continue reading
The Verge |
This company is making an at-home CRISPR kit to find out what’s making you sick
The Verge A new biotech company co-founded by CRISPR pioneer Jennifer Doudna is developing a device that uses CRISPR to detect all kids of diseases like malaria, tuberculosis, and Zika. The tech is still just in prototype phase, but research in the field is … A New Startup Wants to Use Crispr to Diagnose DiseaseWIRED Mammoth Biosciences launches a CRISPR-powered search engine for disease detectionTechCrunch Home Tests in Mind, Doudna Startup Races Rivals in CRISPR DiagnosticsXconomy Endpoints News –San Francisco Business Times all 12 news articles » |
|
Spinout from Jennifer Doudna’s UC lab looks to turn CRISPR into an easy-to-use diagnostic tool
San Francisco Business Times A UC Berkeley spinout hoping to make disease detection as simple as at-home pregnancy tests looks to take the hot CRISPR gene-editing technology in a new direction. Mammoth Biosciences Inc. is emerging from stealth mode with a license for technology … |
CBC.ca |
‘This is not experimental anymore’: How immunotherapy is being …
CBC.ca This is an excerpt from Second Opinion, a weekly roundup of eclectic and under-the-radar health and medical science news emailed to subscribers every Saturday morning. If you haven’t subscribed yet, you can do that by clicking here. Last Monday … Better lung cancer treatment? Immunotherapy drug Keytruda boosts …Genetic Literacy Project |
Medscape |
What’s the Total Cost of One CAR T-Cell Treatment?
Medscape When the first therapies based on chimeric antigen receptor (CAR) T cells were launched last year, the price of the drugs led to some sharp intakes of breath throughout the medical community. Tisagenlecleucel (Kymriah, Novartis) was priced at $475,000 … Risk Versus Reward: The Value of Cell Therapy for Patients and InvestorsInvestorIdeas.com (press release) |